Dimpy P Shah1, Carolyn Z Grimes, Anh T Nguyen, Dejian Lai, Lu-Yu Hwang. 1. Dimpy P. Shah, Carolyn Z. Grimes, Anh T. Nguyen, and Lu-Yu Hwang are with the Center for Infectious Diseases, Division of Epidemiology, Human Genetics and Environmental Sciences, The University of Texas School of Public Health, Houston. Dejian Lai is with the Division of Biostatistics, The University of Texas School of Public Health.
Abstract
OBJECTIVES: We demonstrated the effectiveness of an accelerated hepatitis B vaccination schedule in drug users. METHODS: We compared the long-term effectiveness of accelerated (0-1-2 months) and standard (0-1-6 months) hepatitis B vaccination schedules in preventing hepatitis B virus (HBV) infections and anti-hepatitis B (anti-HBs) antibody loss during 2-year follow-up in 707 drug users (HIV and HBV negative at enrollment and completed 3 vaccine doses) from February 2004 to October 2009. RESULTS:Drug users in the accelerated schedule group had significantly lower HBV infection rates, but had a similar rate of anti-HBs antibody loss compared with the standard schedule group over 2 years of follow-up. No chronic HBV infections were observed. Hepatitis C positivity at enrollment and age younger than 40 years were independent risk factors for HBV infection and antibody loss, respectively. CONCLUSIONS: An accelerated vaccination schedule was more preferable than a standard vaccination schedule in preventing HBV infections in drug users. To overcome the disadvantages of a standard vaccination schedule, an accelerated vaccination schedule should be considered in drug users with low adherence. Our study should be repeated in different cohorts to validate our findings and establish the role of an accelerated schedule in hepatitis B vaccination guidelines for drug users.
RCT Entities:
OBJECTIVES: We demonstrated the effectiveness of an accelerated hepatitis B vaccination schedule in drug users. METHODS: We compared the long-term effectiveness of accelerated (0-1-2 months) and standard (0-1-6 months) hepatitis B vaccination schedules in preventing hepatitis B virus (HBV) infections and anti-hepatitis B (anti-HBs) antibody loss during 2-year follow-up in 707 drug users (HIV and HBV negative at enrollment and completed 3 vaccine doses) from February 2004 to October 2009. RESULTS: Drug users in the accelerated schedule group had significantly lower HBV infection rates, but had a similar rate of anti-HBs antibody loss compared with the standard schedule group over 2 years of follow-up. No chronic HBV infections were observed. Hepatitis C positivity at enrollment and age younger than 40 years were independent risk factors for HBV infection and antibody loss, respectively. CONCLUSIONS: An accelerated vaccination schedule was more preferable than a standard vaccination schedule in preventing HBV infections in drug users. To overcome the disadvantages of a standard vaccination schedule, an accelerated vaccination schedule should be considered in drug users with low adherence. Our study should be repeated in different cohorts to validate our findings and establish the role of an accelerated schedule in hepatitis B vaccination guidelines for drug users.
Authors: V Anna Gyarmathy; Alan Neaigus; Maureen Miller; Samuel R Friedman; Don C Des Jarlais Journal: J Acquir Immune Defic Syndr Date: 2002-08-01 Impact factor: 3.731
Authors: D V Potsch; L A B Camacho; S Tuboi; L M Villar; J C Miguel; C Ginuíno; E F Silva; R M M Mendonça; R B Moreira; P F Barroso Journal: Vaccine Date: 2012-07-21 Impact factor: 3.641
Authors: M Wiedmann; U G Liebert; U Oesen; H Porst; M Wiese; S Schroeder; U Halm; J Mössner; F Berr Journal: Hepatology Date: 2000-01 Impact factor: 17.425
Authors: Christopher S Murrill; Howard Weeks; Brian C Castrucci; Hillard S Weinstock; Beth P Bell; Catherine Spruill; Marta Gwinn Journal: Am J Public Health Date: 2002-03 Impact factor: 9.308
Authors: Gianluca Quaglio; Giorgio Talamini; Fabio Lugoboni; Alessandro Lechi; Luca Venturini; Don C Des Jarlais; Paolo Mezzelani Journal: Addiction Date: 2002-08 Impact factor: 6.526
Authors: Tonny Ssekamatte; John Bosco Isunju; Joan Nankya Mutyoba; Moses Tetui; Richard K Mugambe; Aisha Nalugya; Winnifred K Kansiime; Chenai Kitchen; Wagaba Brenda; Patience Oputan; Justine Nnakate Bukenya; Esther Buregyeya; Simon P S Kibira Journal: PLoS One Date: 2022-05-19 Impact factor: 3.752
Authors: C Brouard; J Pillonel; P Sogni; A Chollet; J V Lazarus; X Pascal; F Barin; M Jauffret-Roustide Journal: Epidemiol Infect Date: 2017-01-19 Impact factor: 4.434